We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases ...
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya ...
March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and ...